EXTON, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) (Fibrocell) today announced that it intends to offer and sell shares of its common stock and related warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and related warrants will be immediately separable and will be issued separately. All of the securities in the offering are to be sold by Fibrocell.
Fibrocell intends to use the net proceeds of the proposed offering for the continued clinical and pre-clinical development of its product candidates and for other general corporate purposes.
Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. Roth Capital Partners, LLC and Griffin Securities, Inc. are acting as co-managers for the offering. Fibrocell intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock and warrants sold in the public offering to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The offering is being made by Fibrocell pursuant to a shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission (the SEC), which the SEC declared effective on February 9, 2016. The offering will be made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. Copies of the preliminary prospectus supplement may also be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, New York, NY 10022; Attention: Equity Capital Markets; Phone: (212) 915-1210; Email: Eric.Sivin@cantor.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced gene-therapy product candidate, FCX-007, has begun a Phase I/II trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its gene-therapy product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third gene-therapy program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene-therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.
Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
This press release contains, and Fibrocell’s officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, Fibrocell’s expectations regarding the sale of shares of its common stock in the proposed public offering, its use of the proceeds from the proposed offering and other statements that are not purely statements of historical fact.
Any forward-looking statement made by Fibrocell in this press release is based only on information currently available to Fibrocell and speaks only as of the date on which it is made. In addition, Fibrocell operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Fibrocell disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Fibrocell’s most recent Form 10-K and Form 10-Q filings as well as Fibrocell’s other public filings with the SEC since the filing of its most recent Form 10-K.
CONTACT: Investor Relations Contact: John Woolford Westwicke Partners 443.213.0506 firstname.lastname@example.org